美国三大医药商业企业的启示

2017-04-25 医药史立臣 美国三大医药商业企业的启示

美国这三大医药商业企业,占据了大约90%的美国医药商业份额。这三个商业企业之所以能够在诸多的医药商业企业竞争中存活,主要是其业态并不单纯是配送批发,而是向上下游延伸,构建了较为全面的增值服务体系

横向比较国外的医药商业企业的发展,可以让现有的医药商业企业获得更多的转型思考路径。美国的医药商业企业,基本被麦克森、康德乐和美源伯根掌控。美国这三大医药商业企业,占据了大约90%的美国医药商业份额。这三个商业企业之所以能够在诸多的医药商业企业竞争中存活,主要是其业态并不单纯是配送批发,而是向上下游延伸,构建了较为全面的增值服务体系,从而增强了产业链的粘合度和掌控度,强化了自身的服务能力,最终形成了三家对美国医药商业市场的绝对掌控。我们来看一下美国三大医药商业企业的业务结构:麦克森公司为美国最大的医药保健分销企业。最大的一部分业务立足于它的药品批发,通过其分布在全美各地的30个分销中心向全美50个州批发药品、保健及化妆品、医疗用品及设备。位居2016年财富美国500强的第五位,2014年销售收入达到1380亿美元。康德乐,作为美国第二大医药保健产品批发商的康德乐健康,2014年销售收入达到910亿美元,净利率为0.3%。美源伯根,美国第三大医药保健品批发商为美源伯根,上市之前,该公司已经经历了一系列整合,并购了许多小型药品批发企业。上市后,公司加快了并购步伐。2014年销售收入达到891

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1771730, encodeId=a9111e7173030, content=<a href='/topic/show?id=62754005931' target=_blank style='color:#2F92EE;'>#商业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40059, encryptionId=62754005931, topicName=商业)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd6238344589, createdName=zhangxingru, createdTime=Tue Dec 12 12:57:00 CST 2017, time=2017-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1408897, encodeId=9aff140889e02, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Thu Apr 27 00:57:00 CST 2017, time=2017-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1456068, encodeId=f05c14560683a, content=<a href='/topic/show?id=3cdb2563088' target=_blank style='color:#2F92EE;'>#企业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25630, encryptionId=3cdb2563088, topicName=企业)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a765759005, createdName=hyf030, createdTime=Thu Apr 27 00:57:00 CST 2017, time=2017-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1535033, encodeId=f615153503332, content=<a href='/topic/show?id=3df58e521e9' target=_blank style='color:#2F92EE;'>#药商#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87521, encryptionId=3df58e521e9, topicName=药商)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c72d12584423, createdName=soongzhihua, createdTime=Thu Apr 27 00:57:00 CST 2017, time=2017-04-27, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1771730, encodeId=a9111e7173030, content=<a href='/topic/show?id=62754005931' target=_blank style='color:#2F92EE;'>#商业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40059, encryptionId=62754005931, topicName=商业)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd6238344589, createdName=zhangxingru, createdTime=Tue Dec 12 12:57:00 CST 2017, time=2017-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1408897, encodeId=9aff140889e02, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Thu Apr 27 00:57:00 CST 2017, time=2017-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1456068, encodeId=f05c14560683a, content=<a href='/topic/show?id=3cdb2563088' target=_blank style='color:#2F92EE;'>#企业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25630, encryptionId=3cdb2563088, topicName=企业)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a765759005, createdName=hyf030, createdTime=Thu Apr 27 00:57:00 CST 2017, time=2017-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1535033, encodeId=f615153503332, content=<a href='/topic/show?id=3df58e521e9' target=_blank style='color:#2F92EE;'>#药商#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87521, encryptionId=3df58e521e9, topicName=药商)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c72d12584423, createdName=soongzhihua, createdTime=Thu Apr 27 00:57:00 CST 2017, time=2017-04-27, status=1, ipAttribution=)]
    2017-04-27 cathymary
  3. [GetPortalCommentsPageByObjectIdResponse(id=1771730, encodeId=a9111e7173030, content=<a href='/topic/show?id=62754005931' target=_blank style='color:#2F92EE;'>#商业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40059, encryptionId=62754005931, topicName=商业)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd6238344589, createdName=zhangxingru, createdTime=Tue Dec 12 12:57:00 CST 2017, time=2017-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1408897, encodeId=9aff140889e02, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Thu Apr 27 00:57:00 CST 2017, time=2017-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1456068, encodeId=f05c14560683a, content=<a href='/topic/show?id=3cdb2563088' target=_blank style='color:#2F92EE;'>#企业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25630, encryptionId=3cdb2563088, topicName=企业)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a765759005, createdName=hyf030, createdTime=Thu Apr 27 00:57:00 CST 2017, time=2017-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1535033, encodeId=f615153503332, content=<a href='/topic/show?id=3df58e521e9' target=_blank style='color:#2F92EE;'>#药商#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87521, encryptionId=3df58e521e9, topicName=药商)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c72d12584423, createdName=soongzhihua, createdTime=Thu Apr 27 00:57:00 CST 2017, time=2017-04-27, status=1, ipAttribution=)]
    2017-04-27 hyf030
  4. [GetPortalCommentsPageByObjectIdResponse(id=1771730, encodeId=a9111e7173030, content=<a href='/topic/show?id=62754005931' target=_blank style='color:#2F92EE;'>#商业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40059, encryptionId=62754005931, topicName=商业)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd6238344589, createdName=zhangxingru, createdTime=Tue Dec 12 12:57:00 CST 2017, time=2017-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1408897, encodeId=9aff140889e02, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Thu Apr 27 00:57:00 CST 2017, time=2017-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1456068, encodeId=f05c14560683a, content=<a href='/topic/show?id=3cdb2563088' target=_blank style='color:#2F92EE;'>#企业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25630, encryptionId=3cdb2563088, topicName=企业)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a765759005, createdName=hyf030, createdTime=Thu Apr 27 00:57:00 CST 2017, time=2017-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1535033, encodeId=f615153503332, content=<a href='/topic/show?id=3df58e521e9' target=_blank style='color:#2F92EE;'>#药商#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87521, encryptionId=3df58e521e9, topicName=药商)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c72d12584423, createdName=soongzhihua, createdTime=Thu Apr 27 00:57:00 CST 2017, time=2017-04-27, status=1, ipAttribution=)]

相关资讯

这四个问题是医药商业未来发展的前提

目前医药商业企业面临的首先是以怎样国家认可的模式生存下去,这就为现在诸多医药商业企业的转型提出了较高的要求。

纯销商业生存和发展的前景几何?

随着两票制、营改增、金税三期等政策的落地,医药商业必将发生大的改变,有些类型的医药商业发展潜力巨大,而有些医药商业将面临死亡。

慢性病患者在美国到底被多重视?

慢性病患者在美国的重视程度到底有多大?中国的重视程度与美国相比到底相差多远?翻阅资料、细看深究,希望能从中找寻到可以借鉴的精华之处......

抗美援朝老班长该拿什么来拯救他的花季孙女

爷爷年轻时曾参加抗美援朝战争,在战场上与美国兵拼刺刀都没怕过,如今孙女的病是他唯一的伤。

不同商业企业生存和发展的思考

随着两票制、营改增、金税三期等政策的落地,必将发生大的改变,有些类型的医药商业发展潜力巨大,而有些医药商业将面临死亡。

政策压力下医药商业企业转型的思考!

我国医药商业结构,随着两票制、营改增、金税三期等政策的落地,必将发生大的改变,所以,增加对上下游的增值服务来获得合理的、更高的利润,是现在很多医药商业企业必须考虑的问题。